Impact of Ferric Citrate vs Ferrous Sulfate on Iron Parameters and Hemoglobin in Individuals With CKD and Iron Deficiency

Completed · Not applicable

Conditions studied: Chronic Kidney Disease, Iron Deficiency, Anemia

In brief

The main objective of the study is to compare the impact of oral ferric citrate compared to standard of care oral ferrous sulfate on serum iron, percent transferrin saturation, ferritin, hepcidin and hemoglobin levels in individuals with moderate to severe chronic kidney disease (CKD) and absolute iron deficiency.

Key facts

Study ID

NCT02888171

Run by

University of Alabama at Birmingham

People needed

60

Starts

2016-09-01

Expected to finish

2019-03-30

Last updated by the study team

2020-03-24

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age 18 years or greater
• Moderate to severe CKD not requiring dialysis (eGFR 15 - 45 ml/min/1.73 m2 by CKD-EPI)
• Absolute iron deficiency (serum ferritin <300ng/ml and Transferrin Saturation < 30%)

You may not qualify if…

• Hemoglobin concentrations > 13 g/dL
• Known disorder of iron homeostasis (e.g., hemochromatosis)
• Known gastrointestinal disorder (irritable bowel disease, inflammatory bowel disease)
• Known liver disease (ALT/AST or bilirubin > 3x normal)
• Serum phosphorus concentrations < 3.0 mg/dL
• Any known cause of anemia other than iron deficiency or CKD (e.g., sickle cell anemia)
• Symptomatic gastrointestinal bleeding within 12 weeks prior to the screening visit.
• Subjects receiving any form of renal replacement therapy including hemodialysis, peritoneal dialysis, or renal transplant.
• Pregnancy or lactation in female participants
• Severe anemia defined as a hemoglobin < 8.0 g/dL for males or a hemoglobin <7.0 g/dL for females.
• Receipt of erythropoiesis stimulating agents within 4 weeks of screening.
• Receipt of intravenous iron therapy within 8 weeks of screening.
• Blood transfusion within 4 weeks of screening
• Known allergies or severe adverse reactions to previous oral iron therapy
• Current use of oral phosphorus binders.
• Current use of an active vitamin D analog

Where it is running

• University of Alabama at Birmingham — Birmingham, Alabama, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.